Cisplatin is an alkylating agent widely used in chemotherapy against different types of cancer in both children and adults. The TPMT enzyme is involved in its metabolism, so polymorphisms in this gene are associated with adverse treatment reactions such as hearing loss.
Cisplatin (Adverse Reactions)
Cisplatin, or cis-diamminedichloroplatinum(II), is a well-known metal-based chemotherapeutic drug used in the standard treatment of various solid cancers such as testicular, breast, ovarian, head and neck, bladder, lung, cervical, stomach, melanoma, neuroblastoma, osteosarcoma, and lymphomas. Depending on the type of cancer, cisplatin can be used alone or with other compounds such as, for example, paclitaxel, in the treatment of ovarian cancer.
Two of the main limitations of cisplatin use are treatment resistance and toxicity. Multiple platinum compounds have been produced to minimize the development of treatment resistance and improve pharmacokinetic properties. Some of the platinum compounds alternative to cisplatin are carboplatin, oxaliplatin, satraplatin, and nedaplatin.
The main toxicities derived from cisplatin treatment are nephrotoxicity, ototoxicity, hepatotoxicity, gastrointestinal toxicity, and neurotoxicity.
MECHANISM OF ACTION
The main mechanism through which cisplatin exerts its action is the interaction with genomic and mitochondrial DNA and the generation of damage in its structure, activating apoptosis (cell death).
CONTRAINDICATIONS
Cisplatin should be avoided in patients with hypersensitivity to cisplatin or other platinum-based compounds, renal dysfunction, dehydration, myelosuppression, hearing impairment, or neuropathy caused by cisplatin.
SIDE EFFECTS
Cisplatin is a medication that can cause toxicity and multiple adverse effects including: infections, sepsis, hematological disorders (leukopenia, thrombocytopenia, and anemia), low blood sodium levels, venous thromboembolism, peripheral neuropathy, hearing loss, vertigo, cardiac arrhythmia, erythema, skin ulcer, and localized edema.
Cisplatin ototoxicity is one of the most frequent adverse reactions, manifesting as permanent bilateral hearing loss, affecting 10-25% of adults and 26-90% of children.
TRADE NAMES
- Platinol®
- Platinol-AQ®
Genes analyzed
Bibliography
Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019 Jul;88:102925.
Lee JW, Pussegoda K, Rassekh SR, et al. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. Ther Drug Monit. 2016 Aug;38(4):423-31.
Thiesen S, Yin P, Jorgensen AL, et al. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenet Genomics. 2017 Jun;27(6):213-222.
